Literature DB >> 19332421

11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease.

V L Villemagne1, C A McLean, K Reardon, A Boyd, V Lewis, G Klug, G Jones, D Baxendale, C L Masters, C C Rowe, S J Collins.   

Abstract

OBJECTIVE: Brain amyloid imaging using positron emission tomography (PET) is of increasing importance in the premortem evaluation of dementias, particularly in relation to Alzheimer disease (AD). The purpose of this study was to explore the premortem diagnostic utility of (11)C-PiB PET in sporadic Creutzfeldt-Jakob disease (CJD).
METHODS: Two patients, 72 and 59 years old, underwent evaluation for rapidly progressive cognitive decline, dying after illness durations of 5 and 7 months, respectively. As part of their comprehensive assessment, (18)F-FDG PET and (11)C-PiB PET studies were performed approximately 2-4 weeks prior to death, and the brain regional distributions compared with those from cohorts of healthy controls (HC) and AD patients.
RESULTS: Routine investigations, including brain MRI scans, revealed changes typical of sporadic CJD, with the diagnosis confirmed at autopsy in both patients. The (18)F-FDG PET showed global hypometabolism in one patient and thalamic and frontal hypometabolism with unexpected hypermetabolism in the dentate nuclei of the cerebellum in the other. Neither patient displayed cerebral cortical (11)C-PiB PET retention above the levels observed in HC.
CONCLUSIONS: No grey-matter (11)C-PiB retention was observed in two pathologically confirmed cases of typical sporadic CJD. We speculate that low PrP plaque density and small plaque size, as well as a relatively low affinity of the radioligand, explain the absence of (11)C-PiB retention. More studies to validate this hypothesis are warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19332421     DOI: 10.1136/jnnp.2008.171496

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Julie C Price; Ronald L Hamilton; Chester A Mathis; William R Paljug; Manik L Debnath; Anne D Cohen; Katsuyoshi Mizukami; Steven T DeKosky; Oscar L Lopez; William E Klunk
Journal:  Acta Neuropathol       Date:  2012-01-24       Impact factor: 17.088

3.  Metabolic patterns in prion diseases: an FDG PET voxel-based analysis.

Authors:  Elena Prieto; Inés Domínguez-Prado; Mario Riverol; Sara Ortega-Cubero; María Jesús Ribelles; María Rosario Luquin; Purificación de Castro; Javier Arbizu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-04       Impact factor: 9.236

4.  Amyloid- and FDG-PET in sporadic Creutzfeldt-Jakob disease: Correlation with pathological prion protein in neuropathology.

Authors:  Jordi A Matías-Guiu; Carmen Guerrero-Márquez; María Nieves Cabrera-Martín; Ulises Gómez-Pinedo; María Romeral; Diego Mayo; Jesús Porta-Etessam; Teresa Moreno-Ramos; José Luis Carreras; Jorge Matías-Guiu
Journal:  Prion       Date:  2017-05-16       Impact factor: 3.931

5.  Disclosure of amyloid imaging results to research participants: has the time come?

Authors:  Jennifer H Lingler; William E Klunk
Journal:  Alzheimers Dement       Date:  2013-02-13       Impact factor: 21.566

Review 6.  Amyloid-β positron emission tomography imaging probes: a critical review.

Authors:  Vladimir Kepe; Mateen C Moghbel; Bengt Långström; Habib Zaidi; Harry V Vinters; Sung-Cheng Huang; Nagichettiar Satyamurthy; Doris Doudet; Eyal Mishani; Robert M Cohen; Poul F Høilund-Carlsen; Abass Alavi; Jorge R Barrio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  In vivo detection of prion amyloid plaques using [(11)C]BF-227 PET.

Authors:  Nobuyuki Okamura; Yusei Shiga; Shozo Furumoto; Manabu Tashiro; Yoshio Tsuboi; Katsutoshi Furukawa; Kazuhiko Yanai; Ren Iwata; Hiroyuki Arai; Yukitsuka Kudo; Yasuhito Itoyama; Katsumi Doh-ura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-17       Impact factor: 9.236

Review 8.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

Review 9.  Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.

Authors:  G D Rabinovici; W J Jagust
Journal:  Behav Neurol       Date:  2009       Impact factor: 3.342

10.  [(11)C]PiB PET in Gerstmann-Sträussler-Scheinker disease.

Authors:  Kacie D Deters; Shannon L Risacher; Karmen K Yoder; Adrian L Oblak; Frederick W Unverzagt; Jill R Murrell; Francine Epperson; Eileen F Tallman; Kimberly A Quaid; Martin R Farlow; Andrew J Saykin; Bernardino Ghetti
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.